Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $37.2 million.

  • Zentalis Pharmaceuticals' Total Current Liabilities fell 3227.04% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year decrease of 3227.04%. This contributed to the annual value of $52.7 million for FY2024, which is 2399.12% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Total Current Liabilities stood at $37.2 million for Q3 2025, which was down 3227.04% from $39.0 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Total Current Liabilities high stood at $69.4 million for Q4 2023, and its period low was $37.2 million during Q3 2025.
  • Its 4-year average for Total Current Liabilities is $52.9 million, with a median of $54.1 million in 2022.
  • In the last 5 years, Zentalis Pharmaceuticals' Total Current Liabilities skyrocketed by 2960.33% in 2023 and then plummeted by 4148.92% in 2025.
  • Zentalis Pharmaceuticals' Total Current Liabilities (Quarter) stood at $56.6 million in 2022, then increased by 22.45% to $69.4 million in 2023, then dropped by 23.99% to $52.7 million in 2024, then fell by 29.51% to $37.2 million in 2025.
  • Its Total Current Liabilities stands at $37.2 million for Q3 2025, versus $39.0 million for Q2 2025 and $49.4 million for Q1 2025.